Skip to content
On Monday afternoon, Moderna’s shares increased by 25 per cent.
Since the beginning of the year, the pre-clinical company has increased its stock by 241 percent;
one of the first companies to report plans for the development of a vaccine, as of January 23, and its mRNA candidate is generally considered to be a first-rate in the development of the first virus vaccine.
It is now the first company to announce clinical results of a human vaccine.
In the Phase 1 clinical trial people received Moderna Inc. MRNA, a candidate of -6.19% for coronavirus vaccine developed neutralising antibodies which led the vaccine to the next phase of clinical trials, a promising finding.
The enterprise also announced on Monday that it will sell $1.34 billion in its inventory to help fund the production of the COVID-19 experimental vaccine.